CJJD [CHINA JO-JO DRUGSTORES] 10-K: (Original Filing)

[TABLE OF CONTENTS TO ANNUAL REPORT ON FORM 10-K FOR YEAR ENDED MARCH 31, 2015 Page PART I. Item 1. Business. 4 Item 1A. Risk Factors. 23 Item 1B. Unresolved Staff Comments. 43 Item 2. Properties. 44 Item 3. Legal Proceedings. 44 Item 4. Mine Safety Disclosures. 44 PART II. Item 5. 45 Item 6. Selected Financial Data. 45 Item] [List of Subsidiaries 1. Renovation Investment (Hong Kong) Co., Ltd. (“Renovation”) is a Hong Kong company and is wholly-owned by the Company. 2. Hangzhou Jiutong Medical Technology Co., Ltd. (“Jiutong Medical”) is a Chinese company and is wholly-owned by Renovation. 3. Zhejiang Shouantang Pharmaceutical Technology Co., Ltd. (“Shouantang Technology”) is a Chinese company and is wholly-owned by Renovation. 4. Zhejiang] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements of China Jo-Jo Drugstores, Inc. and its subsidiaries on Form S-3 (No. 333-198001) and Form S-8 (No. 333-171849) of our report dated June 26, 2015 relating to the consolidated financial statements which appear in this Annual Report on Form 10-K. June] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-198001) and Form S-8 (No. 333-171849) of China Jo-Jo Drugstores, Inc. and subsidiaries of our report dated June 27, 2014 relating to the consolidated financial statements, which appear in this Form 10-K. Friedman LLP New York, New] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lei Liu, certify that: (1) I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ming Zhao, certify that: (1) I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Lei Liu Chief Executive Officer Ming Zhao Chief Financial Officer (Principal Financial and Accounting Officer) June 29,]

CJJD [CHINA JO-JO DRUGSTORES] 10-K: TABLE OF CONTENTS TO ANNUAL REPORT ON FORM

[TABLE OF CONTENTS TO ANNUAL REPORT ON FORM 10-K FOR YEAR ENDED MARCH 31, 2015 Page PART I. Item 1. Business. 4 Item 1A. Risk Factors. 23 Item 1B. Unresolved Staff Comments. 43 Item 2. Properties. 44 Item 3. Legal Proceedings. 44 Item 4. Mine Safety Disclosures. 44 PART II. Item 5. 45 Item 6. Selected Financial Data. 45 Item] [List of Subsidiaries 1. Renovation Investment (Hong Kong) Co., Ltd. (“Renovation”) is a Hong Kong company and is wholly-owned by the Company. 2. Hangzhou Jiutong Medical Technology Co., Ltd. (“Jiutong Medical”) is a Chinese company and is wholly-owned by Renovation. 3. Zhejiang Shouantang Pharmaceutical Technology Co., Ltd. (“Shouantang Technology”) is a Chinese company and is wholly-owned by Renovation. 4. Zhejiang] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements of China Jo-Jo Drugstores, Inc. and its subsidiaries on Form S-3 (No. 333-198001) and Form S-8 (No. 333-171849) of our report dated June 26, 2015 relating to the consolidated financial statements which appear in this Annual Report on Form 10-K. June] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-198001) and Form S-8 (No. 333-171849) of China Jo-Jo Drugstores, Inc. and subsidiaries of our report dated June 27, 2014 relating to the consolidated financial statements, which appear in this Form 10-K. Friedman LLP New York, New] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lei Liu, certify that: (1) I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ming Zhao, certify that: (1) I have reviewed this annual report on Form 10-K of China Jo-Jo Drugstores, Inc.; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Lei Liu Chief Executive Officer Ming Zhao Chief Financial Officer (Principal Financial and Accounting Officer) June 29,]

CJJD [CHINA JO-JO DRUGSTORES] 8-K: (Original Filing)

[China Jo-Jo Drug Stores Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2015 Q4 Revenue grew 30.1%, EPS jumped to $0.03/share from Losses of $1.01/share FY 2015 Online Pharmacy Sales Increased 96.8%, Gross Profit up 117.2% and EPS Improved to $0.06 from Losses of $1.83 HANGZHOU, China, June 29, 2015 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ] []

CJJD [CHINA JO-JO DRUGSTORES] 8-K: China Jo-Jo Drug Stores Announces Fourth Quarter and

[China Jo-Jo Drug Stores Announces Fourth Quarter and Year End Financial Results for Fiscal Year 2015 Q4 Revenue grew 30.1%, EPS jumped to $0.03/share from Losses of $1.01/share FY 2015 Online Pharmacy Sales Increased 96.8%, Gross Profit up 117.2% and EPS Improved to $0.06 from Losses of $1.83 HANGZHOU, China, June 29, 2015 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ] []

TAOM [Taomee] 6-K: (Original Filing)

[Taomee Holdings Limited Announces Retention of Legal and Financial Advisors by the Special Committee to Consider “Going Private Proposal” Special Committee Board SHANGHAI, June 26, 2015 — Taomee Holdings Limited (NYSE: TAOM) (“Taomee” or the “Company”), one of the leading children’s entertainment and media companies in China, today announced that following the formation of the special committee consisting of three] [TAOMEE HOLDINGS LIMITED 16/F, Building No. A-2, No. 1528 Gumei Road, Xuhui District Shanghai 200233, People’s Republic of China (86-21) 6128-0056 Form 20-F x o o o Yes o No x 82- N/A TAOMEE HOLDINGS LIMITED]

By | 2016-04-01T09:23:03+00:00 June 29th, 2015|Categories: Chinese Stocks, SEC Original, TAOM|Tags: , , , , , |0 Comments

TAOM [Taomee] 6-K: Taomee Holdings Limited Announces Retention of Legal and

[Taomee Holdings Limited Announces Retention of Legal and Financial Advisors by the Special Committee to Consider “Going Private Proposal” Special Committee Board SHANGHAI, June 26, 2015 — Taomee Holdings Limited (NYSE: TAOM) (“Taomee” or the “Company”), one of the leading children’s entertainment and media companies in China, today announced that following the formation of the special committee consisting of three] [TAOMEE HOLDINGS LIMITED 16/F, Building No. A-2, No. 1528 Gumei Road, Xuhui District Shanghai 200233, People’s Republic of China (86-21) 6128-0056 Form 20-F x o o o Yes o No x 82- N/A TAOMEE HOLDINGS LIMITED]

By | 2016-04-01T09:23:56+00:00 June 29th, 2015|Categories: Chinese Stocks, TAOM, Webplus ver|Tags: , , , , , |0 Comments

HSOL [Hanwha Q CELLS] CORRESP: (Original Filing)

[June 29, 2015 VIA EDGAR Division of Corporation Finance 100 F Street, NE Attention: Ms. Amanda Ravitz – Assistant Director Ms. Kristin Lochhead – Reviewing Accountant Mr. Gary Todd – Reviewing Accountant Mr. Tom Jones – Special Counsel Mr. Dan Morris – Special Counsel Re: Hanwha Q CELLS Co., Ltd. Amendment No. 1 to Registration Statement on Form F-3 Filed]

HSOL [Hanwha Q CELLS] CORRESP: June 29, 2015 VIA EDGAR Division of Corporation

[June 29, 2015 VIA EDGAR Division of Corporation Finance 100 F Street, NE Attention: Ms. Amanda Ravitz – Assistant Director Ms. Kristin Lochhead – Reviewing Accountant Mr. Gary Todd – Reviewing Accountant Mr. Tom Jones – Special Counsel Mr. Dan Morris – Special Counsel Re: Hanwha Q CELLS Co., Ltd. Amendment No. 1 to Registration Statement on Form F-3 Filed]

By | 2016-04-02T23:55:58+00:00 June 29th, 2015|Categories: Chinese Stocks, HSOL, Webplus ver|Tags: , , , , , |0 Comments

HSOL [Hanwha Q CELLS] F-3/A: (Original Filing)

[CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1)(2) Proposed Maximum Aggregate Offering Price(3)(4) Amount of Registration Fee Ordinary shares, par value US$0.0001 per share(5) Preferred shares Debt securities Total US$500,000,000 US$58,100 (1) (2) The securities being registered also include such indeterminate number of securities as may be issued upon exercise, conversion or exchange of other] [DATED THIS 29 DAY OF JUNE 2009 BETWEEN GOVERNMENT OF MALAYSIA (the “Lender”) AND Q-CELLS MALAYSIA SDN. BHD. (COMPANY NO. 810647-M) (the “Borrower”) FACILITY AGREEMENT Table of Content Page Clause 1. Interpretation 1 2. The Facility 4 3. Conditions Precedent 5 4. Procedure For Drawdown 6 5.] [BETWEEN GOVERNMENT OF MALAYSIA (“Lender”) AND Q-CELLS MALAYSIA SDN. BHD. (Company No. 810647-M) (“Borrower”) SUPPLEMENTAL FACILITY AGREEMENT THIS SUPPLEMENTAL FACILITY AGREEMENT BETWEEN: (1) GOVERNMENT OF MALAYSIA Lender The AND (2) Q-CELLS MALAYSIA SDN. BHD. Borrower Parties Party (hereinafter collectively referred to as the “ WHEREAS: (A) Principal Agreement (B) Original Guarantor Existing Guarantee Original Debenture (C) Hanwha MOF Hanwha Q.CELLS] [Loan Agreement between Hanwha SolarOne Co., Ltd. as Borrower and The Export-Import Bank of Korea as Lender Dated as of December 22, 2014 TABLE OF CONTENTS Page Section 1. Definitions and Interpretation 2 Section 2. The Facility 4 Section 3. Disbursement 4 Section 4. Interest, Default Interest and Fees 5 Section 5. Repayment and Prepayment 7 Section 6. Security 7] [EXEUCTION COPY OAN GREEMENT L US$120,000,000 dated as of April 21, 2015 among HANWHA Q CELLS CO., LTD. as Borrower THE KOREA DEVELOPMENT BANK as Mandated Lead Arranger THE BANKS AND OTHER FINANCIAL INSTITUTIONS named herein as Lenders and KDB ASIA LIMITED as Agent CONTENTS Section Page Section 1. Interpretation 1 Section 2. The Facility 4 Section 3. The Drawdown] [*** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 203.406 PHOTOVOLTAIC MODULE MASTER SUPPLY AGREEMENT BETWEEN NEXTERA ENERGY RESOURCES, LLC AND HANWHA SOLARONE U.S.A. INC. Dated as of April 11, 2015 TABLE OF CONTENTS SECTION PAGE 1. PRODUCT SALES AND PURCHASE. 1 2. PRICES; PAYMENT; TAXES. 3 3. RIGHT OF FIRST OFFER 5 4.] [Consent of Independent Registered Public Accounting Firm Shanghai, the People’s Republic of China June 29, 2015 EX-23.1 7 d884862dex231.htm EX-23.1] [Consent of Independent Auditor’s Report We consent to the use of our report dated April 24, 2015, with respect to the consolidated balance sheets of Hanwha Q CELLS Investment Co., Ltd. as of December 31, 2013 and 2014 and the related consolidated statements of operations and comprehensive income (loss), changes in stockholders’ equity and cash flows for the period from] [Consent of Independent Registered Public Accounting Firm We hereby consent to the use in this Registration Statement on Amendment No. 2 to Form F-3 of Hanwha Q CELLS Co., Ltd. of our report dated March 17, 2015 relating to the financial statements of Hanwha Q Cells Malaysia SDN. BHD., which appears in such Registration Statement. We also consent to the]

By | 2016-04-02T23:59:43+00:00 June 29th, 2015|Categories: Chinese Stocks, HSOL, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar